Literature DB >> 23121190

Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.

Emiliano Bissio, Gustavo D Lopardo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23121190      PMCID： PMC3581036          DOI： 10.1089/AID.2012.0233

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  14 in total

1.  Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

Authors:  Ian Sanne; Peter Piliero; Kathleen Squires; Alexandra Thiry; Steven Schnittman
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

2.  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Authors:  Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Anna Rightmire; Serap Sankoh; Richard Wilber
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

3.  Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.

Authors:  Tim O Lankisch; Ulrike Moebius; Michael Wehmeier; Georg Behrens; Michael P Manns; Reinhold E Schmidt; Christian P Strassburg
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

4.  Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Authors:  Sonia Rodríguez Nóvoa; Pablo Barreiro; Ana Rendón; Ana Barrios; Angélica Corral; Inmaculada Jiménez-Nacher; Juan González-Lahoz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2005-12-08       Impact factor: 9.079

5.  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

Authors:  Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

6.  Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Authors:  Kathleen Squires; Adriano Lazzarin; José M Gatell; William G Powderly; Vadim Pokrovskiy; Jean-François Delfraissy; Joseph Jemsek; Antonio Rivero; Willy Rozenbaum; Shannon Schrader; Michael Sension; Asda Vibhagool; Alexandra Thiry; Michael Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

Review 7.  Atazanavir.

Authors:  Joanne J Orrick; Corklin R Steinhart
Journal:  Ann Pharmacother       Date:  2004-09-07       Impact factor: 3.154

Review 8.  Clinical pharmacology, efficacy and safety of atazanavir: a review.

Authors:  Danièle Bentué-Ferrer; Cédric Arvieux; Olivier Tribut; Annick Ruffault; Eric Bellissant
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-11       Impact factor: 4.481

9.  Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Authors:  D R Malan; Edrich Krantz; Neal David; Victoria Wirtz; Janet Hammond; Donnie McGrath
Journal:  J Acquir Immune Defic Syndr       Date:  2008-02-01       Impact factor: 3.731

10.  Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

Authors:  Robin Wood; Praphan Phanuphak; Pedro Cahn; Vadim Pokrovskiy; Willy Rozenbaum; Giuseppe Pantaleo; Michael Sension; Robert Murphy; Marco Mancini; Thomas Kelleher; Michael Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2004-06-01       Impact factor: 3.731
View more
  3 in total

1.  Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.

Authors:  Hossein Mazaherpour; Masoomeh Sofian; Elham Farahani; Alireza Abdi; Sakine Mazaherpour; Anahita Bavand; Amitis Ramezani
Journal:  Biomed Res Int       Date:  2022-01-07       Impact factor: 3.411

2.  Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.

Authors:  Lindsey Devisscher; Mathieu Vinken; Eva Gijbels; Vânia Vilas-Boas; Pieter Annaert; Tamara Vanhaecke
Journal:  Arch Toxicol       Date:  2020-03-10       Impact factor: 5.153

Review 3.  Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis.

Authors:  Shannon L Turvey; Lynora Saxinger; Andrew L Mason
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.